The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the standard 60-minute infusion of alteplase.

Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...

A study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...

It is important to not ignore a mini stroke as it can be a warning sign of a brain stroke. According to Mayo Clinic, about 1 ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Every year, millions of people die from stroke. In order to win against this disease which occurs the moment when a blood ...

Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...

Though arterial thrombotic risk was higher with hormonal contraception use, the absolute excess risks were low.

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...